A review on RNAi therapy for NSCLC: Opportunities and challenges
Non-small cell lung cancer (NSCLC) is the primary cause of cancer death worldwide. Despite developments in chemotherapy and targeted therapies, the 5-year survival rate has remained at approximately 16% for the last four decades. NSCLC is a heterogeneous group of tumors that, through mutations and d...
Saved in:
Published in | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Vol. 13; no. 2; p. e1677 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
01.03.2021
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Non-small cell lung cancer (NSCLC) is the primary cause of cancer death worldwide. Despite developments in chemotherapy and targeted therapies, the 5-year survival rate has remained at approximately 16% for the last four decades. NSCLC is a heterogeneous group of tumors that, through mutations and drivers, also demonstrate intra-tumor heterogeneity. Thus, current treatment approaches revolve around targeting these oncogenes, often using small molecule inhibitors and chemotherapeutics. However, the efficacy of these therapies has been crippled by acquired and inherent drug-resistance in the tumor, accompanied by increased therapeutic dosages and subsequent devastating off-target effects for patients. Evidently, there is a critical need for developing treatment methodologies more effective than the current standard of care. Fortunately, RNA interference, particularly small interfering RNA (siRNA), presents an alternative of silencing specific oncogenes to control tumor growth. Although siRNA therapy is subject to rapid degradation and poor internalization in vivo, nanoparticles can serve as nontoxic and efficient delivery vehicles, even introducing combinational delivery of multiple therapeutic agents. Indeed, siRNA-nanoconstructs possess extraordinary potential as an innovative modality to address clinical needs. This state-of-the-art review summarizes the recent advancements in the development of novel nanosystems for delivering siRNA to NSCLC tumors and analyzes the efficacy of representative examples. By illuminating the most promising biomarkers for silencing, we hope to streamline current therapeutic efforts and highlight powerful translational opportunities to combat NSCLC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology-Inspired Nanomaterials > Lipid-Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease. |
---|---|
AbstractList | Non-small cell lung cancer (NSCLC) is the primary cause of cancer death worldwide. Despite developments in chemotherapy and targeted therapies, the 5-year survival rate has remained at approximately 16% for the last four decades. NSCLC is a heterogeneous group of tumors that, through mutations and drivers, also demonstrate intra-tumor heterogeneity. Thus, current treatment approaches revolve around targeting these oncogenes, often using small molecule inhibitors and chemotherapeutics. However, the efficacy of these therapies has been crippled by acquired and inherent drug-resistance in the tumor, accompanied by increased therapeutic dosages and subsequent devastating off-target effects for patients. Evidently, there is a critical need for developing treatment methodologies more effective than the current standard of care. Fortunately, RNA interference, particularly small interfering RNA (siRNA), presents an alternative of silencing specific oncogenes to control tumor growth. Although siRNA therapy is subject to rapid degradation and poor internalization in vivo, nanoparticles can serve as nontoxic and efficient delivery vehicles, even introducing combinational delivery of multiple therapeutic agents. Indeed, siRNA-nanoconstructs possess extraordinary potential as an innovative modality to address clinical needs. This state-of-the-art review summarizes the recent advancements in the development of novel nanosystems for delivering siRNA to NSCLC tumors and analyzes the efficacy of representative examples. By illuminating the most promising biomarkers for silencing, we hope to streamline current therapeutic efforts and highlight powerful translational opportunities to combat NSCLC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology-Inspired Nanomaterials > Lipid-Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease. |
Author | Kannan, Raghuraman Yadavilli, Sairam Kumar, Vignesh |
Author_xml | – sequence: 1 givenname: Vignesh surname: Kumar fullname: Kumar, Vignesh organization: Department of Radiology, University of Missouri, Columbia, Missouri, USA – sequence: 2 givenname: Sairam surname: Yadavilli fullname: Yadavilli, Sairam organization: Department of Radiology, University of Missouri, Columbia, Missouri, USA – sequence: 3 givenname: Raghuraman orcidid: 0000-0003-1980-3797 surname: Kannan fullname: Kannan, Raghuraman organization: Department of Radiology, University of Missouri, Columbia, Missouri, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33174364$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8tKw0AYRgdR7EUXvoDMC6TOP5PMJK4MoV4gtOBlXebyj42kkzBJLX17C-rq45zFgW9GzkMXkJAbYAtgjN8dgg4LkEqdkSkUokgYS2FCZsPwxZhMJc8uyUQIUKmQ6ZQ8lDTid4MH2gX6uiobOm4x6v5IfRfp6q2qq3u67vsujvvQjA0OVAdH7Va3LYZPHK7IhdftgNd_Oycfj8v36jmp108vVVknVmRCJQacZxaUMgVA7tFKmXKtMi2Ys9oiqNyk3ruTyIxB5_kJtdPAIQfJHZ-T299uvzc7dJs-Njsdj5v_K_wHpqVJ6Q |
CitedBy_id | crossref_primary_10_1016_j_jconrel_2022_08_005 crossref_primary_10_3389_fimmu_2022_987881 crossref_primary_10_2478_raon_2023_0033 crossref_primary_10_1186_s12964_024_01574_1 crossref_primary_10_1186_s12943_021_01338_2 crossref_primary_10_1186_s12935_021_01749_7 crossref_primary_10_1007_s11010_022_04569_z crossref_primary_10_3389_fphar_2023_1148171 crossref_primary_10_1021_acsabm_2c00845 crossref_primary_10_1186_s12951_021_01085_y crossref_primary_10_1038_s41392_021_00648_7 crossref_primary_10_1016_j_jconrel_2022_10_061 crossref_primary_10_1007_s11095_022_03443_3 crossref_primary_10_1515_med_2022_0613 crossref_primary_10_1016_j_poly_2022_116025 crossref_primary_10_1111_1759_7714_14994 |
ContentType | Journal Article |
Copyright | 2020 Wiley Periodicals LLC. |
Copyright_xml | – notice: 2020 Wiley Periodicals LLC. |
DBID | NPM |
DOI | 10.1002/wnan.1677 |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1939-0041 |
ExternalDocumentID | 33174364 |
Genre | Journal Article Review |
GroupedDBID | --- 05W 0R~ 1OC 1VH 31~ 33P 4.4 53G 5DZ 8-0 8-1 8UM A00 AAESR AAHHS AANLZ AASGY AAXRX AAZKR ABCUV ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACIWK ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADKYN ADMGS ADXAS ADZMN AEEZP AEIGN AEQDE AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE AJXKR ALMA_UNASSIGNED_HOLDINGS ALUQN AMYDB ASPBG AUFTA AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMNLL BMXJE BRXPI DCZOG DRFUL DRMAN DRSTM EBS EJD EMOBN F5P FEDTE G-S GODZA HGLYW HVGLF HZ~ KBYEO LATKE LEEKS LITHE LOXES LUTES LYRES MEWTI MRFUL MRSTM MSFUL MSSTM MXFUL MXMAN MXSTM MY. MY~ NPM O66 O9- P2W ROL SUPJJ SV3 WBKPD WHWMO WIH WIK WOHZO WVDHM WXSBR WYJ XV2 ZZTAW |
ID | FETCH-LOGICAL-c3537-b1df0c177b9118fec6642a75a30dcace178b4ffd5a35bbedf2b4fada1218162d2 |
IngestDate | Tue Aug 27 13:48:33 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | drug-resistance nanoparticle siRNA NSCLC chemotherapy |
Language | English |
License | 2020 Wiley Periodicals LLC. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3537-b1df0c177b9118fec6642a75a30dcace178b4ffd5a35bbedf2b4fada1218162d2 |
ORCID | 0000-0003-1980-3797 |
PMID | 33174364 |
ParticipantIDs | pubmed_primary_33174364 |
PublicationCentury | 2000 |
PublicationDate | 2021-Mar |
PublicationDateYYYYMMDD | 2021-03-01 |
PublicationDate_xml | – month: 03 year: 2021 text: 2021-Mar |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology |
PublicationTitleAlternate | Wiley Interdiscip Rev Nanomed Nanobiotechnol |
PublicationYear | 2021 |
SSID | ssj0064625 |
Score | 2.3914986 |
SecondaryResourceType | review_article |
Snippet | Non-small cell lung cancer (NSCLC) is the primary cause of cancer death worldwide. Despite developments in chemotherapy and targeted therapies, the 5-year... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | e1677 |
Title | A review on RNAi therapy for NSCLC: Opportunities and challenges |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33174364 |
Volume | 13 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4NAEN5UTYwejO-32YM3QwUWFvRk02iM0ZrUR_Rk9ll7KG1q1cT4451lAWmrRr2Qslug3e9jmBl2vkVoV4jYJZoIJ2ZUOQHzpBMHjDk00jKmoaB-msy5aNDTm-DsLryrVN7L1SUDXhVvX9aV_AdVaANcTZXsH5AtTgoN8BnwhS0gDNtfYVwrKk-SvWaj1t6z1VR2Dmbjqn5eNwH_Zc_42M9Jqp1q69jyFVSeyr6pNRBGP6I_VKubCZZWjSXu5u_i0_Mk0MDb3cFYer6YuH3bboEtLVLO90yyF5Phscnodp91ikNYki2V3GStx2foyXibpST80pysqrJm9IAcOEbKa8jOkhKf_JLRVB61S7mMmXMrD_sKl6-OfgfGr9dJcSXERFVWC_3n3hFl7bxrAk1EsbGODZPpsU9xGkBgmCtRuf5-8Rtm0HR-3Egkknok1_NoLgslcM3yYgFVVLKIZksCk0voqIYteribYMMQnDEEA0NwypBDPMQPDLjiT34so5uT4-v6qZOtmeEIEpLI4Z7UrvCiiMNTLNZKUAgwWRQy4krBhPKimAdaS2gIOVdS-7AL2HvG1aO-9FfQZNJN1BrC3HcJCyA854oHLKQ8lOBvMkEg6NU8VOto1f79h54VRnnIB2bj255NNPNJmC00peFOVNvg1g34Tjr-HxhQUOY |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+review+on+RNAi+therapy+for+NSCLC%3A+Opportunities+and+challenges&rft.jtitle=Wiley+interdisciplinary+reviews.+Nanomedicine+and+nanobiotechnology&rft.au=Kumar%2C+Vignesh&rft.au=Yadavilli%2C+Sairam&rft.au=Kannan%2C+Raghuraman&rft.date=2021-03-01&rft.eissn=1939-0041&rft.volume=13&rft.issue=2&rft.spage=e1677&rft_id=info:doi/10.1002%2Fwnan.1677&rft_id=info%3Apmid%2F33174364&rft_id=info%3Apmid%2F33174364&rft.externalDocID=33174364 |